Simris Group ABProfessor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
ADVERTISEMENT